News
INO
4.195
+3.33%
0.135
The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals
Benzinga · 4d ago
Inovio Pharma Price Target Cut to $5.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 4d ago
Inovio Pharma Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $5
Benzinga · 4d ago
Inovio Pharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 4d ago
Inovio Pharma Price Target Cut to $15.00/Share From $33.00 by Oppenheimer
Dow Jones · 4d ago
Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15
Benzinga · 4d ago
Inovio price target lowered to $15 from $33 at Oppenheimer
TipRanks · 4d ago
Cautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive Pressures
TipRanks · 4d ago
Inovio price target lowered to $5 from $12 at H.C. Wainwright
TipRanks · 4d ago
Weekly Report: what happened at INO last week (1111-1115)?
Weekly Report · 4d ago
U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals
Reuters · 4d ago
Inovio Pharmaceuticals: Strategic Progress and Promising Pipeline Justify Buy Rating
TipRanks · 4d ago
INOVIO PHARMACEUTICALS INC <INO.O>: OPPENHEIMER CUTS TARGET PRICE TO $15 FROM $33
Reuters · 4d ago
Inovio Pharma Price Target Cut to $6.00/Share From $7.00 by RBC Capital
Dow Jones · 11/15 17:41
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Dow Jones · 11/15 17:41
RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $6
Benzinga · 11/15 17:31
Inovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail Sentiment
Barchart · 11/15 16:32
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Benzinga · 11/15 16:21
INOVIO PHARMACEUTICALS INC <INO.O>: JEFFERIES CUTS TARGET PRICE TO $5 FROM $9.50
Reuters · 11/15 15:07
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.